title: Interval debulking surgery in patients with Federation of Gynecology and Obstetrics (FIGO) stage IIIC and IV ovarian cancer.
abstract: BACKGROUND
  The feasibility of neoadjuvant chemotherapy (NAC) and the outcome in patients with Federation of Gynecology and Obstetrics (FIGO) IIIC and IV ovarian cancer were assessed.
  
  
  METHODS
  67 patients undergoing interval debulking surgery (IDS) and ≥ 4 courses of platinum-based NAC were analyzed for survival, perioperative morbidity and mortality.
  
  
  RESULTS
  The median follow-up was 30 months. The median progression-free survival (PFS) was 17 months, the overall survival (OS) 34 months. The PFS of patients without residual disease (n = 23; 34.3%) was 31 months (p = 0.003), the OS 65 months (p = 0.001). PFS and OS were significantly longer in patients with no residual disease than in patients with 1-10 mm (n = 34; 47.9%) (p = 0.005 and p = 0.0001, respectively) residual disease. No survival benefit was seen for patients with 1-10 mm compared to > 1 cm (n = 12; 16.9%) residual disease (PFS p = 0.518; OS p = 0.077). 1 patient (1.4%) died; 12 patients needed interventional treatment or operation (16.9%) within the first 30 days postoperatively. Out of these, 5 patients (7.0%) had residual or lasting disability.
  
  
  CONCLUSIONS
  NAC and IDS are safe and feasible in this series of patients with unfavorable prognosis. IDS does not change the goal of complete cytoreduction and therefore does not compensate for a less radical surgical approach.
authors.affiliation: Bonn University Medical Center, Department of Obstetrics and Gynecology, Center for Integrated Oncology Köln-Bonn, Bonn, Germany. mignon-denise.paik@ukb.uni-bonn.de
authors.forename: Mignon-Denise
authors.initials: MD
authors.lastname: Keyver-Paik
authors.forename: Oliver
authors.initials: O
authors.lastname: Zivanovic
authors.forename: Christian
authors.initials: C
authors.lastname: Rudlowski
authors.forename: Tobias
authors.initials: T
authors.lastname: Höller
authors.forename: Matthias
authors.initials: M
authors.lastname: Wolfgarten
authors.forename: Kirsten
authors.initials: K
authors.lastname: Kübler
authors.forename: Lars
authors.initials: L
authors.lastname: Schröder
authors.forename: Michael R
authors.initials: MR
authors.lastname: Mallmann
authors.forename: Michael
authors.initials: M
authors.lastname: Mallmann
authors.forename: Martin
authors.initials: M
authors.lastname: Pölcher
authors.forename: Walther
authors.initials: W
authors.lastname: Kuhn
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D017024:Chemotherapy, Adjuvant / Q000401:mortality*; D005260:Female; D005858:Germany / Q000453:epidemiology; D013509:Gynecologic Surgical Procedures / Q000401:mortality*; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000401:mortality* / Q000517:prevention & control*; D010051:Ovarian Neoplasms / Q000401:mortality* / Q000628:therapy*; D015995:Prevalence; D012307:Risk Factors; D016019:Survival Analysis; D015996:Survival Rate; D016896:Treatment Outcome; D055815:Young Adult